Dr. Hammers on Immunotherapy Combinations in Kidney Cancer

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Since nivolumab (Opdivo) has been approved, it has changed the treatment landscape for patients with kidney cancer, states Hammers. However, ongoing studies have been looking to combine nivolumab with other agents to increase the response.

Combining nivolumab with VEGF inhibitors is an area that has shown particular promise, explains Hammers. The trials investigating these combinations have shown encouraging data.